Home › NDC Lookup › RxCUI directory › RxCUI 2636840

Sodium oxybate 9000 MG Granules for Oral Suspension [Lumryz] — RxCUI 2636840

RxNorm drug concept · Semantic branded drug
RxCUI 2636840 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2636840
Official nameSodium oxybate 9000 MG Granules for Oral Suspension [Lumryz]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asLumryz 9000 MG Granules for Oral Suspension; Lumryz 9 GM Granules for extended release Oral Suspension; Lumryz 9 GM (equivalent to 7.4 GM oxybate) Granules for Oral Suspension
FDA products mapped5
Package NDCs mapped9
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sodium Oxybate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That's a great question, and the answer depends on which product you're prescribed. If you're on Xyrem or the generic oral solution, yes — you do need two doses spaced about 2.5 to...
  • Why do I have to take two doses in the middle of the night — can't I just take it all at once?
  • No — alcohol and sodium oxybate absolutely cannot be mixed, even if there are hours between them. Combining the two dramatically increases the risk of your breathing slowing down d...
  • Can I have a glass of wine with dinner if I take my dose hours later at bedtime?
📖 Read our full Sodium Oxybate guide →

🕸️ Concept Web — How Sodium oxybate 9000 MG Granules for Oral Suspens... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sodium oxybate 9000 MG Granules for Oral Suspension [Lumryz] RxCUI 2636840

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Oxybate 2387302
    • Sodium oxybate 9899
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lumryz 2636823
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Oxybate Granules for Oral Suspension 2636821
    • Sodium oxybate Granules for Oral Suspension 2645962
    • Oxybate Granule Product 2636820
    • Oxybate Oral Product 2392731
    • Sodium oxybate Granule Product 2662340
    • Sodium oxybate Oral Product 2660169
    • Oxybate Granules for Oral Suspension [Lumryz] 2636827
    • Sodium oxybate Granules for Oral Suspension [Lumryz] 2658015
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sodium oxybate 9000 MG Granules for Oral Suspension SCD · 2636838
  • Sodium oxybate 9000 MG SCDC · 2636837
  • Oxybate Granules for Oral Suspension SCDF · 2636821
  • Sodium oxybate Granules for Oral Suspension SCDFP · 2645962
  • Oxybate Granule Product SCDG · 2636820
  • Oxybate Oral Product SCDG · 2392731
  • Sodium oxybate Granule Product SCDGP · 2662340
  • Sodium oxybate Oral Product SCDGP · 2660169

Brand-Name Concepts

  • Sodium oxybate 9000 MG [Lumryz] SBDC · 2636839
  • Oxybate Granules for Oral Suspension [Lumryz] SBDF · 2636827
  • Sodium oxybate Granules for Oral Suspension [Lumryz] SBDFP · 2658015
  • Lumryz Granule Product SBDG · 2636826
  • Lumryz Oral Product SBDG · 2636825
  • Lumryz BN · 2636823

📦 FDA Products & Package NDCs

5 products · 9 package NDCs
9 package NDCs map to RxCUI 2636840 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
13551-0001-07 7 PACKET in 1 CARTON (13551-001-07) / 1 FOR SUSPENSION, EXT... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0001-30 30 PACKET in 1 CARTON (13551-001-30) / 1 FOR SUSPENSION, EX... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0002-07 7 PACKET in 1 CARTON (13551-002-07) / 1 FOR SUSPENSION, EXT... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0002-30 30 PACKET in 1 CARTON (13551-002-30) / 1 FOR SUSPENSION, EX... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0003-07 7 PACKET in 1 CARTON (13551-003-07) / 1 FOR SUSPENSION, EXT... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0003-30 30 PACKET in 1 CARTON (13551-003-30) / 1 FOR SUSPENSION, EX... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0004-07 7 PACKET in 1 CARTON (13551-004-07) / 1 FOR SUSPENSION, EXT... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0004-30 30 PACKET in 1 CARTON (13551-004-30) / 1 FOR SUSPENSION, EX... Lumryz Avadel CNS Pharmaceuticals, LLC 2023-05-01
13551-0005-01 1 KIT in 1 CARTON (13551-005-01) * 1 FOR SUSPENSION, EXTEN... Lumryz Avadel CNS Pharmaceuticals, LLC 2024-10-07
Observed labelers: Avadel CNS Pharmaceuticals, LLC (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.